GENVIVO, INC.
🇺🇸United States
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor, Adult
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- GenVivo, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT06391918
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Southern California-Keck School of Medicine, Los Angeles, California, United States
🇺🇸Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
GEN2 Directed Cancer Immunotherapy Trial
Phase 1
Completed
- Conditions
- Hepatocellular CarcinomaMetastatic Cancer
- Interventions
- Drug: GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- GenVivo, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT04313868
- Locations
- 🇵🇭
Makati Medical Center, Makati City, Philippines
🇵🇭The Medical City, Pasig City, Philippines
🇵🇭National Kidney and Transplant Institute, Quezon City, Philippines
News
No news found